Amylin Pharmaceuticals Buys $10M Stake In BioSeek, Pens Drug-Discovery Alliance | GenomeWeb
BioSeek this week said that Amylin Pharmaceuticals has bought a $10 million stake in the company, and that the firms have penned a joint research collaboration to discover and develop treatments for inflammatory conditions.
Encouraged by the success of its previous collaboration with BioSeek, Amylin would like to help the company evolve from a fee-for-service shop into a drug discovery company, according to Michael Hanley, vice president of discovery research for Amylin.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.